Gsk
$497M 13F equity value
13 Holdings
Quarter ended September 30, 2026
The latest 13F on file for Gsk covers the quarter ended September 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| CRSP | CRISPR THERAPEUTICS AG | 2,608,419 | $144M | 29.0% |
| VIR | VIR BIOTECHNOLOGY INC | 8,550,954 | $96M | 19.2% |
| WVE | WAVE LIFE SCIENCES INC | 18,245,691 | $68M | 13.6% |
| BNTX | BIONTECH SE | 668,526 | $66M | 13.2% |
| IDYA | IDEAYA BIOSCIENCES INC | 1,333,333 | $51M | 10.3% |
| CYTK | CYTOKINETICS INC | 340,434 | $22M | 4.5% |
| LYEL | LYELL IMMUNOPHARMA INC | 1,512,659 | $15M | 3.0% |
| SPRO | SPERO THERAPEUTICS INC | 9,190,606 | $11M | 2.2% |
| NKTX | NKARTA INC | 3,150,732 | $8M | 1.7% |
| FULC | FULCRUM THERAPEUTICS INC | 1,785,714 | $7M | 1.3% |
Track Gsk's 13F portfolio: $497M in reported holdings, 13 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}